Products Pembrolizumab was approved as an infusion product in the United States in 2014 and in the EU and many countries in 2015 (Keytruda). Structure and properties Pembrolizumab is a humanized monoclonal antibody. It is an IgG4-κ immunoglobulin with a molecular weight of approximately 149 kDa. Effects Pembrolizumab (ATC L01XC18) has antitumor and immunomodulatory properties. … Pembrolizumab
Symptoms Melanomas are discolored, growing, skin lesions that arise from pigmented moles in about 30% of cases. They are found primarily on the skin, but can occur anywhere melanocytes are found, including the oral mucosa, respiratory tract, or eye, for example. In men they are most common on the upper body, in women on the … Melanoma Causes and Treatment
Products The first therapeutic monoclonal antibody was approved in 1986. Muromonab-CD3 (Orthoclone OKT3) binds to the CD3 receptor on T cells and has been used in transplantation medicine. Numerous drugs containing antibodies are now available. A selection of active substances can be found at the end of this article. These are expensive drugs. For example, … Monoclonal Antibodies
Products Durvalumab was approved as an infusion product in the United States in 2017 and in many countries and the EU in 2018 (Imfinzi). Structure and properties Durvalumab is a human IgG1κ monoclonal antibody. It is produced by biotechnological methods. Effects Durvalumab (ATC L01XC28) has selective immunostimulatory and antitumor properties. The effects are due to … Durvalumab
